Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Endosome Therapeutics Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located in 1 distinct art unit, reflecting a very focused prosecution profile. This concentration suggests that the company's current efforts at the USPTO are centered on a specific therapeutic innovation within the biotechnology sector.
The busiest examiner for this portfolio is WARD, PAUL V, who is currently managing 1 pending office action. Because the busiest examiner pending count of 1 is equal to the total number of pending office actions, the company's immediate patent prospects are tied to the review of this single individual. There are no other active matters to provide a comparison or to diversify the company's interactions with the USPTO staff.
For a practitioner, the alignment of 1 distinct examiner and 1 distinct art unit means that the prosecution strategy must be highly targeted toward the expectations of WARD, PAUL V. The success of the 1 pending office action is critical for the portfolio's progress in the Biotechnology & Pharmaceuticals field. Practitioners must rely on the specific feedback from this examiner to guide the company's intellectual property strategy at this stage.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18823317 | Tripartite Modulators of Endosomal G Protein-Coupled Receptors | WARD, PAUL V | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18823317 | Tripartite Modulators of Endosomal G Protein-Coupled Receptors | WARD, PAUL V | 1622 | §112DP | Non-Final OA | — | Pending | Sep 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEndosome Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul V Ward has the most, with 1 of Endosome Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
